AIIMS-Delhi is among the 12 sites chose by the Indian Council for Medical Research (ICMR) for leading stage I and II human trials of Covaxin. In phase I, the vaccine would be tried on 375 volunteers and a limit of 100 of them would be from AIIMS.
“The AIIMS Ethics Committee gave its approval for beginning the human clinical trial of the indigenously developed Covaxin today. Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial,” Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS said.
“Few volunteers have already registered for the trial. We would start the screening of the individuals and evaluate their health condition from Monday onwards before vaccinating them,” Rai, who is also the principal investigator of the study, said.
The country`s top drug regulator had recently gave a green signal for human clinical trials for COVID-19 vaccine candidate Covaxin, which has been developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV).
Anybody willing to participate in the trial can send an email to [email protected] or an SMS to or call on 7428847499, he said. The institute may also put up these contact details on its website.
According to Rai, the Ethics Committee had raised few concerns in the protocol submitted for carrying out of the trial.